TW201118083A - Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate - Google Patents

Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Download PDF

Info

Publication number
TW201118083A
TW201118083A TW099126051A TW99126051A TW201118083A TW 201118083 A TW201118083 A TW 201118083A TW 099126051 A TW099126051 A TW 099126051A TW 99126051 A TW99126051 A TW 99126051A TW 201118083 A TW201118083 A TW 201118083A
Authority
TW
Taiwan
Prior art keywords
crystal form
pharmaceutical composition
single crystal
ray powder
formula
Prior art date
Application number
TW099126051A
Other languages
English (en)
Chinese (zh)
Inventor
David A Claremon
Robert D Simpson
Lan-Qi Jia
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of TW201118083A publication Critical patent/TW201118083A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW099126051A 2009-08-06 2010-08-05 Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate TW201118083A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23186009P 2009-08-06 2009-08-06

Publications (1)

Publication Number Publication Date
TW201118083A true TW201118083A (en) 2011-06-01

Family

ID=42797342

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099126051A TW201118083A (en) 2009-08-06 2010-08-05 Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Country Status (8)

Country Link
US (2) US8372978B2 (enExample)
EP (1) EP2462137A1 (enExample)
JP (1) JP2013501072A (enExample)
CN (1) CN102656166A (enExample)
AR (1) AR077692A1 (enExample)
IN (1) IN2012DN01905A (enExample)
TW (1) TW201118083A (enExample)
WO (1) WO2011017533A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2440993C2 (ru) 2004-10-07 2012-01-27 Вайти Фармасьютикл, Инк. Диаминоалкановые ингибиторы аспарагиновой протеазы
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US9896429B2 (en) 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
CN106536501A (zh) 2014-05-27 2017-03-22 R.J.雷诺兹烟草公司 烟碱盐、共晶体和盐共晶体络合物
US10508096B2 (en) 2014-05-27 2019-12-17 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3071618A (en) * 1956-02-02 1963-01-01 Pfizer & Co C Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
US4136163A (en) * 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
JPS5115098A (ja) 1974-07-26 1976-02-06 Asahi Chemical Ind Akurirukeiseniseihinno shorihoho
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en) 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
CA2081564C (en) 1990-05-11 1998-02-03 Anthony Andrea Fossa Synergistic therapeutic compositions and methods
DE4018070A1 (de) * 1990-06-06 1991-12-12 Bayer Ag Morpholinoharnstoff-derivate
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
EP0561973A1 (en) * 1990-12-14 1993-09-29 Merrell Dow Pharmaceuticals Inc. Antiallergic compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
CA2129995C (en) * 1992-02-13 2000-04-11 Albert A. Carr Piperidinyl thiacyclic derivatives
DK0644755T3 (da) 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
ATE187160T1 (de) 1994-07-29 1999-12-15 Abbott Lab Verfahren zur herstellung eines substituierten 2,5-diamino-3-hydroxy hexanes
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
EP0983269A4 (en) 1997-05-29 2001-06-27 Lilly Co Eli PROCESSES USEFUL FOR THE PREPARATION OF HETEROCYCLIC COMPOUNDS
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) * 1998-12-02 1999-01-27 Darwin Discovery Ltd Process
AU2492500A (en) 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods
JP2000302757A (ja) 1999-04-16 2000-10-31 Shiseido Co Ltd Ｎ−置換ピペリジン誘導体
EA005893B1 (ru) * 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EA200400162A1 (ru) 2001-07-11 2005-06-30 Элан Фармасьютикалз, Инк. N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
GB0121700D0 (en) * 2001-09-07 2001-10-31 Univ Leicester Detection of fluorescence
CA2466284A1 (en) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
UA80819C2 (en) 2002-04-26 2007-11-12 Gilead Sciences Inc Phosphonate analogs of compounds inhibiting hiv proteases, pharmaceutical composition on their basis and their use
WO2004002483A1 (en) 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
WO2004024675A1 (en) 2002-09-10 2004-03-25 Pharmacia & Upjohn Company Llc Substituted aminoethers for the treatment of alzheimer's disease
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
EP1778652A2 (en) 2004-08-20 2007-05-02 EntreMed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
RU2440993C2 (ru) 2004-10-07 2012-01-27 Вайти Фармасьютикл, Инк. Диаминоалкановые ингибиторы аспарагиновой протеазы
EP1882684B1 (en) 2005-05-19 2014-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
CN101356156B (zh) * 2005-11-14 2012-12-05 生命医药公司 天冬氨酸蛋白酶抑制剂
US7858624B2 (en) 2006-04-05 2010-12-28 Vitae Pharmaceuticals, Inc. Piperidine and morpholine renin inhibitors
US7872028B2 (en) * 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
US20090318501A1 (en) * 2006-09-18 2009-12-24 Baldwin John J Piperidine derivatives as renin inhibitors
CL2007002689A1 (es) * 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2009096996A1 (en) 2007-06-20 2009-08-06 Smithkline Beecham Corporation Renin inhibitors
EP2170815A2 (en) 2007-06-20 2010-04-07 Vitae Pharmaceuticals, Inc. Renin inhibitors
US7773441B2 (en) * 2008-06-18 2010-08-10 Micron Technology, Inc. Memory malfunction prediction system and method
WO2009154766A1 (en) 2008-06-20 2009-12-23 Vitae Pharmaceuticals, Inc. Renin inhibitors and method of use thereof
JP2011525933A (ja) * 2008-06-26 2011-09-29 ヴァイティー ファーマシューティカルズ，インコーポレイテッド メチル２−（（ｒ）−（３−クロロフェニル）（（ｒ）−１−（（ｓ）−２−（メチルアミノ）−３−（（ｒ）−テトラヒドロ−２ｈ−ピラン−３−イル）プロピルカルバモイル）ピペリジン−３−イル）メトキシ）エチルカルバメートの塩

Also Published As

Publication number Publication date
WO2011017533A1 (en) 2011-02-10
US20110098321A1 (en) 2011-04-28
JP2013501072A (ja) 2013-01-10
US20130197034A1 (en) 2013-08-01
AR077692A1 (es) 2011-09-14
EP2462137A1 (en) 2012-06-13
IN2012DN01905A (enExample) 2015-07-24
CN102656166A (zh) 2012-09-05
US8372978B2 (en) 2013-02-12

Similar Documents

Publication Publication Date Title
JP4705956B2 (ja) Ｈｉｖインテグラーゼ阻害剤のカリウム塩
JP5714024B2 (ja) ３−（２，６−ジクロロ−３，５−ジメトキシ−フェニル）−１−｛６−［４−（４−エチル−ピペラジン−１−イル）−フェニルアミノ］−ピリミジン−４−イル｝−１−メチル−尿素の結晶形態およびその塩
TW201118083A (en) Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
TW200930713A (en) Nitrogen-containing heterocyclic compound and use thereof
TW200829574A (en) Renin inhibitors and method of use thereof
TW200827326A (en) Organic compounds
US10065922B2 (en) Solabegron zwitterion and uses thereof
JP6230743B1 (ja) ヘテロシクリデンアセトアミド誘導体の結晶
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
TWI731153B (zh) 用於治療神經性起立性低血壓之化合物
JP7038675B2 (ja) 結晶塩形態
TWI895453B (zh) 雜環類化合物的晶型及其製備方法和應用
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
JP2011525933A (ja) メチル２−（（ｒ）−（３−クロロフェニル）（（ｒ）−１−（（ｓ）−２−（メチルアミノ）−３−（（ｒ）−テトラヒドロ−２ｈ−ピラン−３−イル）プロピルカルバモイル）ピペリジン−３−イル）メトキシ）エチルカルバメートの塩
JP2018515566A (ja) 医薬組成物
RU2515557C1 (ru) Фармацевтическая соль 8-метил-7-[5-метил-6-(метиламино)-3-пиридинил]-1-циклопропил-4-оксо-1,4-дигидро-3-хинолинкарбоновой кислоты, ее содержащая фармацевтическая композиция, лекарственное средство и способ лечения или профилактики бактериальных инфекций с помощью вышеуказанной соли
KR20170012332A (ko) [2-[1-(6-메틸-3-피리다지닐)-4-피페리디닐]에톡시]-3-에톡시-1,2-벤즈이속사졸의 무수 결정성 유리 염기 형태
US20220089550A1 (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)-n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
HK40062278A (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)- n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
WO2006086779A1 (en) Amorphous ziprasidone mesylate
HK1258038B (en) Solabegron zwitterion and uses thereof
HK1219484B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法